Back to Search
Start Over
Histone Parylation factor 1 contributes to the inhibition of PARP1 by cancer drugs
- Source :
- Nature Communications, Vol 12, Iss 1, Pp 1-11 (2021)
- Publication Year :
- 2021
- Publisher :
- Nature Portfolio, 2021.
-
Abstract
- PARP1 is the target of clinically approved anti-cancer drugs whose in vivo efficacy has been hard to predict. Here the authors show how an altered active site formed between PARP1 and Histone PARylation Factor 1 (HPF1) changes the efficacy of some of these inhibitors.
- Subjects :
- Science
Subjects
Details
- Language :
- English
- ISSN :
- 20411723
- Volume :
- 12
- Issue :
- 1
- Database :
- Directory of Open Access Journals
- Journal :
- Nature Communications
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.33d6d10fa6924050954dfbd2aa320cee
- Document Type :
- article
- Full Text :
- https://doi.org/10.1038/s41467-021-20998-8